financetom
Business
financetom
/
Business
/
Factbox-How the SEC has bolstered the US market since the 2021 GameStop frenzy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Factbox-How the SEC has bolstered the US market since the 2021 GameStop frenzy
Jun 5, 2024 3:48 AM

WASHINGTON (Reuters) - The latest resurgence of retail trading in GameStop ( GME ) follows major changes aimed at boosting the resilience and transparency of the market following the 2021 "meme stock" saga.

GameStop ( GME ) shares surged on Monday after the stocks influencer "Roaring Kitty" returned to Reddit with a post showing a $116 million bet on the embattled videogame retailer.

It was the first post from the account since 2021 when a meteoric rally in GameStop ( GME ) and other "meme stocks" partly stoked by "Roaring Kitty" caused intense volatility, prompting brokers to restrict trading in some shares and causing massive losses for hedge funds that had bet against them.

Since then, the Securities and Exchange Commission (SEC) has adopted or proposed broad changes to fix structural problems highlighted by that extraordinary episode. Here are the key ones:

T+1 SETTLEMENT

The 2021 meme stock volatility prompted the post-trade clearing house to call on retail brokerages including Robinhood to post billions of dollars in extra collateral to guarantee their retail clients' trades. In response, several brokers restricted trading in the affected stocks.

Robinhood CEO Vlad Tenev said at the time that the problem was largely due the two days it takes trades to settle, and if settlements were in real time so much collateral would not be necessary.

Partly in response to that episode, the SEC has moved U.S. equities, corporate and municipal bonds and other securities, to a one business day settlement cycle, known as T+1 settlement.

That market overhaul went into effect last week.

SHORT SELLING, HEDGE FUND DISCLOSURES

Most of the stocks in the 2021 meme saga were heavily shorted by hedge funds - a strategy used to bet a stock price will fall. While the SEC said in its October 2021 post-mortem that the available data did not suggest foul play when it came to such short sales, SEC Chair Gary Gensler said greater transparency of short selling may be warranted.

The SEC has since adopted new rules to boost hedge fund disclosures around their investment exposures, counterparty exposure and other risks, as well as short selling positions.

Some of its changes are being challenged by the industry in court.

MARKET STRUCTURE

2021 shone a spotlight on what Gensler has said are problems in the retail trading market. Rather than sending customer orders to exchanges, most retail brokers send them to wholesale market makers in return for a fee, a practice known as payment for order flow.

Critics say the practice creates conflicts of interest by incentivizing brokers to encourage customers to trade more frequently. Studies show retail investors generally lose money when they churn their portfolio. The small number of market makers also limits competition, critics argue.

In 2022, the SEC proposed sweeping changes that aim to address these issues, in part by creating more incentives to send retail orders to exchanges. The agency expects to finalize that rule sometime this year, according to its public agenda.

DIGITAL TRADING PROMPTS

Gensler has criticized the "gamification of trading" in which brokerages encourage excessive trading using lights, noises, notifications and other gimmicks to generate more payment for order flow.

He has also highlighted the use of artificial intelligence, predictive data analytics and machine learning to push products.

Last year, the SEC proposed rules requiring broker-dealers to "eliminate or neutralize" any conflict of interest that occurs if a trading platform's predictive data analytics puts the broker's financial interest ahead of clients'.

That rule has run into intense opposition and Gensler last month told reporters he was considering re-proposing it.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Liberty Global Completes Sunrise Spinoff
Liberty Global Completes Sunrise Spinoff
Nov 9, 2024
04:31 PM EST, 11/08/2024 (MT Newswires) -- Liberty Global ( LBTYA ) said Friday it has completed the spinoff of its Swiss business Sunrise into a separate publicly traded company. The move comes after Liberty shareholders approval on Oct. 25, the company said. Sunrise shares in the form of Sunrise American depository shares will be distributed to Liberty shareholders on...
Carrier Global Insider Sold Shares Worth $12,281,698, According to a Recent SEC Filing
Carrier Global Insider Sold Shares Worth $12,281,698, According to a Recent SEC Filing
Nov 9, 2024
04:58 PM EST, 11/08/2024 (MT Newswires) -- Kevin J. O'Connor, Senior Vice President & Chief Legal Officer, on November 06, 2024, sold 167,183 shares in Carrier Global ( CARR ) for $12,281,698. Following the Form 4 filing with the SEC, O'Connor has control over a total of 46,083 shares of the company, with 46,083 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1783180/000122520824009822/xslF345X05/doc4.xml...
Advanced Micro Devices Insider Sold Shares Worth $11,509,369, According to a Recent SEC Filing
Advanced Micro Devices Insider Sold Shares Worth $11,509,369, According to a Recent SEC Filing
Nov 9, 2024
04:34 PM EST, 11/08/2024 (MT Newswires) -- Lisa T Su, Director, Chair, President & CEO, on November 06, 2024, sold 80,000 shares in Advanced Micro Devices ( AMD ) for $11,509,369. Following the Form 4 filing with the SEC, Su has control over a total of 4,184,892 shares of the company, with 3,566,762 shares held directly and 618,130 controlled indirectly....
Autolus Therapeutics' Leukemia Treatment Receives US FDA Approval
Autolus Therapeutics' Leukemia Treatment Receives US FDA Approval
Nov 9, 2024
04:58 PM EST, 11/08/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said late Friday its Aucatzyl programmed T cell therapy has received marketing authorization from the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The safety of Aucatzyl includes a boxed warning for cytokine release syndrome, neurologic...
Copyright 2023-2026 - www.financetom.com All Rights Reserved